Oral PCSK9 Inhibitors Market Enters High-Growth Phase with LIPFENDRA Approval

The PCSK9 inhibitors market has entered its high-growth phase due to the approval of Merck's LIPFENDRA and the emergence of oral PCSK9 inhibitor drugs. The growing prevalence of hypercholesterolemia, dyslipidemia, and cardiovascular diseases worldwide is driving demand for effective LDL-C-lowering therapies.

The recent approval of LIPFENDRA marks a major milestone in the oral PCSK9 inhibitor market, establishing the first approved oral therapy in this class. Its once-daily oral administration could broaden patient acceptance and address adherence barriers associated with injectable PCSK9 therapies.

Several emerging PCSK9-targeted candidates are under development, including Recaticimab from Hengrui Medicine, VERVE-102 from Verve Therapeutics, AZD0780 from AstraZeneca, AQR-008 from Aqur Biosciences, and others. Among these, Recaticimab represents one of the notable next-generation PCSK9-targeted therapies being evaluated for hypercholesterolemia and cardiovascular risk reduction.

The PCSK9 inhibitors market was found to be USD 3 billion in the 7MM in 2025, with the United States accounting for the largest share. The report also provides insights into the emerging PCSK9 targeted therapies, market share of individual therapies, and current and forecasted market size from 2022 to 2036.